From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
Thalidomide (N = 67) | Bevacizumab (N = 69) | |||
---|---|---|---|---|
N | % | N | % | |
Gender (% male) | 41 | 61.2 | 23 | 33.3 |
Pathogenic gene | ||||
ENG (HHT1) | 17 | 25.4 | 10 | 14.5 |
ACVRL1 (HHT2) | 34 | 50.7 | 57 | 82.6 |
SMAD4 (JPHT) | 2 | 3.0 | 1 | 1.4 |
Not known | 14 | 20.9 | 1 | 1.4 |
Treatment indication | ||||
Epistaxis | 48 | 71.6 | 14 | 20.3 |
GI bleeding | 11 | 16.4 | 8 | 11.6 |
Epistaxis and GI bleeding | 8 | 11.9 | 10 | 14.5 |
High output cardiac failure | 0 | 0 | 37 | 53.6 |